Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited: Q1 2026 Financial Analysis

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (“Da Ren Tang Group”) has reported its financial results for the first quarter ended 31 March 2026. The company, a major player in Traditional Chinese Medicine (TCM), maintains listings on both the Singapore Exchange (SGX) and Shanghai Stock Exchange (SSE). This article provides a detailed analysis of the company’s key financial metrics, performance trends, and outlook, based strictly on the disclosed financial statements.

Key Financial Metrics and Quarter Comparisons

Performance Review and Trends

• Revenue Growth: The Group delivered a 4% revenue increase YoY, driven by higher sales from major product lines.
• Gross Margin Expansion: Gross profit grew 10%, with gross margin rising to 76% (up 4 percentage points), mainly due to favorable product mix.
• Net Profit: Net profit attributable to owners increased by 13% YoY, reflecting solid operational leverage.
• Earnings Per Share: EPS grew 12% YoY, from RMB 0.49 to RMB 0.55.
• Dividend: No dividend has been declared for the quarter; this is in line with the same period last year.
• Cash Flow: Net cash flow from operating activities increased substantially to RMB 418.86 million, up from RMB 95.79 million in Q1 2025, mainly due to lower tax payments compared to the previous year.

Exceptional Earnings and Expenses

• Other Gains: Other income and gains increased 21% YoY, primarily due to a RMB 2.23 million gain from the liquidation of Tianjin Biochip Technology Co., Ltd.
• Other Losses: Other losses jumped to RMB 38.66 million (up 134%) due to increased provision for inventory obsolescence.
• R&D and Administrative Expenses: R&D expenses were up 16% YoY, reflecting the company’s commitment to innovation. Administrative expenses rose 6% YoY, mainly driven by increased brand promotion efforts.
• Finance Costs: Finance costs decreased, benefitting from lower borrowing costs.

Balance Sheet Highlights

• Trade and Other Receivables: Increased 14% QoQ, indicating strong sales but also possible slower collections.
• Inventories: Decreased 5%, likely reflecting improved inventory management or sales acceleration.
• Cash and Cash Equivalents: Down 11% QoQ, largely due to payment of dividends declared in 2025.
• Other Financial Assets: Decreased 28%, as large certificate-of-deposit products matured and were redeemed for dividend payments.

Industry and Outlook

The TCM industry is undergoing rapid transformation, with policy, market, and technological factors driving both opportunities and challenges. Industry concentration and standardization are increasing, aided by government reforms and international expansion efforts. However, margin compression from centralized procurement, intense competition, supply chain volatility, and talent shortages remain concerns.

Da Ren Tang Group maintains competitive advantages through its strong brand portfolio, exclusive products, and ongoing investment in R&D and brand promotion. The company intends to optimize its product structure, accelerate market development of high-potential products, and strengthen supply chain control.

Related Party Transactions and Fund Flows

• Deposits with Tianjin Pharmaceutical Group Finance Co., Ltd.: RMB 1,309.79 million placed, within the approved maximum limit. These deposits enhance liquidity management, but represent a significant concentration of funds.
• Guarantees: Substantial guarantees provided to related subsidiaries, totaling RMB 433.54 million this quarter.
• No Significant Divestments or Acquisitions: The company reported no material disposals or acquisitions during the quarter.

Chairman’s Statement

“The Company adheres to its core philosophy of ‘upholding tradition while pursuing innovation.’ Leveraging its four (4) major China Time-Honoured Brand clusters including Da Ren Tang and Long Shun Rong, its portfolio of national-level intangible cultural heritage and well-known trademarks, and its accumulated brand heritage valued in the billions of RMB, the Company has built strong competitive barriers. Together with 599 drug approval numbers, 122 exclusive products and a core technology patent portfolio, the Company has reinforced these barriers through national-level confidential products such as Suxiao Jiuxin Wan and Jing Wan Hong, and drives growth momentum through high-growth second-tier products such as Qingyan Diwan and Yatongting Diwan, strengthening synergy across the full value chain. Facing industry opportunities and challenges, the Company will continue to optimise its product portfolio structure and accelerate the market development of second-tier high-potential products; increase investment in R&D innovation and clinical value research to drive commercialisation of technological achievements; deepen refined operations across the full value chain and enhance supply chain control and cost management; and steadily advance brand rejuvenation and international expansion, while accelerating the cultivation of multi-disciplinary talent, to comprehensively strengthen core competitiveness. The Company is committed to capturing industry strategic opportunities, effectively managing risks and challenges, and pursuing sustainable, high-quality long-term development.”

The tone is positive, emphasizing brand strength, innovation, and strategic positioning for sustainable growth.

Conclusion and Investment Recommendation

Overall, Da Ren Tang Group’s Q1 2026 performance appears strong. The company achieved solid revenue and profit growth, expanded margins, and demonstrated resilience amid industry challenges. Increased R&D and brand investments position it well for ongoing transformation, while strong cash flows from operations and responsible liquidity management provide financial stability. However, the absence of a dividend for the quarter and elevated inventory provisions warrant continued monitoring.

For current shareholders: The company’s positive outlook, strong core business, and ongoing investment in innovation suggest it is prudent to continue holding the stock, particularly for investors seeking exposure to the TCM sector’s growth and transformation.

For prospective investors (not currently holding): The results indicate a robust business with a clear growth strategy. Investors may consider initiating a position, but should be aware of sector-specific risks, including regulatory changes, margin pressure, and supply chain volatility.

Disclaimer: This analysis is based solely on the information provided in the company’s Q1 2026 financial report. It does not constitute investment advice. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

View TJ DaRenTang USD Historical chart here